Therapeutic Pipeline Program: Pre-clinical Studies


Event details

Date 28.09.2021  
Category Call for proposal
Event Language English
Aim: This funding program — an Edmond J. Safra Core Program for PD Research — will support development of Parkinson’s disease (PD) therapeutics with potential for fundamentally altering disease course or significantly improving non-motor or motor symptoms.
Program Priorities:
  • Assay development, early screening campaigns, hit-to-lead and lead optimization
  • Proof-of-concept
  • Pharmacokinetics, pharmacodynamics and safety
Studies may request access to MJFF-sponsored biospecimen and cell line collections. 
Researchers from public and private institutions are encouraged to apply and to collaborate. 

Deadline: Pre-proposals due 28 September 2021
Amount: Up to $500,000
Duration: 1 to 2 years
Eligibility: Applications may be submitted by researchers or clinicians in:
  • U.S. and non-U.S. biotechnology/pharmaceutical companies, or other publicly or privately held for-profit entities; and
  • U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government.
  • Post-doctoral fellows are not eligible to apply as co-investigators in this call.
As programs may require many kinds of expertise, MJFF encourages industry and academic collaborations when appropriate.

How to Apply: Further Information:

Practical information

  • Informed public
  • Free


  • The Research Office


Parkinson's Disease motor symptoms non-motor symptoms PD pathogenic mechanisms PD pharmacokinetics pharmacodynamics

Event broadcasted in